Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 8/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.35 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927487 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL31672721 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL29776833 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL19655969 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL19656075 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL30338080 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL1006038 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20927482 | 1.00 | TACR1 (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20927481 | 0.99 | ACHE (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 | |
| SCHEMBL20508875 | 0.99 | ACHE (0.36) | TACR1ACHEBCHEEHMT2SUV39H1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | disclosed |
| US-20170342077-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | CSPP1, CBR3, NPY2R | TACR1 1047/4885ACHE 1089/4885BCHE 1005/4885 |
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | CSPP1, CBR3, NPY2R | TACR1 1047/4885ACHE 1089/4885BCHE 1005/4885 |
| US-20170342077-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | CSPP1, CBR3, NPY2R | TACR1 1047/4885ACHE 1089/4885BCHE 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.